Clinical Trial

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Name: Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) — clinical trial record (NCT06598306)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DeLLphi-308

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Protocol Amendment History 1 change

notable Primary completion pushed: 2027-03-03 -> 2027-04-24 2026-06-27

Trial Details

NCT Number	NCT06598306
Lead Sponsor	Amgen Collaborators: BeOne Medicines
Conditions	Extensive Stage Small Cell Lung Cancer
Enrollment	220 participants
Start Date	2024-10-07
Primary Completion	2027-04-24 (estimated)
Study Completion	2030-04-24 (estimated)
Updated on ClinicalTrials.gov	2026-06-26